All the Little Birdies Go Tweet, Tweet, Tweet

Reuters this week reported that poultry farmers should make sure to prevent sparrows, starlings, and pigeons from entering chicken houses because they could potentially infect poultry with the H5N1 bird flu virus.

I suppose that does make sense, but sounds rather impractical. Small birds have an amazing ability to worm (is that a suitable word?) their way into even the smallest of openings. Chimneys and vents are absolutely no problem for sparrows. It’s only a couple of months ago that I had to dismantle our heating system to release a trapped bird from the flu and there’s a tiny gap (half an inch?) between two roof tiles on our neighbour’s property into which starlings wantonly fly in and out on a daily basis.

Now, picture a chicken farm – I assume they’re referring to battery chickens rather than free range. Every chicken farm I’ve ever seen, and there are quite a few in this locale, has dodgy roof tiles, vents, ducts, openings, doors, even. And, dozens upon dozens of chickens feeding on all kinds of tasty grains and pellets. The temptation for any small bird is just too much and they flock in and out as often as they can get away with.

Admittedly, the article is referring mainly to small chicken coops, that are perhaps a little more manageable. But, that said, a poverty stricken keeper of a few domestic chickens may not have the means to repair one of those dodgy roofs even if it is small.

Regardless of what we do to protect poultry from H5N1 it is not likely that this viral strain specifically will be the culprit when a global pandemic gets underway. There are other strains, there are other viruses, the strain that will be P2P transmissable may already have jumped to another host, such as a pig on a Vietnamese smallholding or a cat in a Hong Kong market cage. It may even have made the leap to humans, in which case it is only a matter of time before it emerges into the wild.

No amount of fixing up chicken coops and keeping the starlings at bay is going to prevent that from happening.

Desktop bird flu test

It always come down to money. From Friday, the ability of London’s financial services industry to cope with a bird flu pandemi will be put to the test as money-oriented firms across The City (London’s financial district) check their metaphorical handkerchiefs and determine whether they are ready or not. So says a report just in from Reuters. In fact, Reuters refers to an “outbreak of a bird flu pandemic”. I’m not sure what that means, an outbreak of a pandemic…but you get the point.

The six-week desktop exercise will figure out whether Britain’s banks, insurers, stock exchange, traders and all the other suit-wearing types will be able to cope with the pandemic. It is important, of course, if a pandemic hits and no one can buy shares in the flu drug manufacturers there would be an immediate crisis. Probably best to stock up now, before they find there’s no way their braces not belt approach will be able to handle it.

Lethal bird flu virus

Although H5N1, the avian influenza virus, darling of a scare-mongering media is lethal. No doubt about it. It’s just that at this point in human history, this virus is not in a human transmissable form, thankfully.

Now, a new study of patients who became infected with H5N1 in Vietnam has revealed clues as to why the virus is so lethal.

Menno de Jong and colleagues compared viral levels and effects on the immune system in one group of patients infected with H5N1 and another group infected with two types of human flu virus. The patients with H5N1 infection had much greater viral load in the throat than the patients infected with the human virus; markers of viral load were highest in the H5N1 patients who died. Virus could also frequently be detected in the blood of H5N1 patients but only in those who died.

The authors found that H5N1 virus at high levels triggers the release of inflammatory cytokines and that levels of these compounds is associated with a higher viral load. Fatal H5N1 infection was also associated with a loss of white blood cells in the peripheral blood.

The authors posit that H5N1 replicates much faster than human flu virus and that the high levels of the virus trigger an overwhelming inflammatory response that contributes to lung dysfunction and eventually death. They report their results in Nature Medicine today.

An important point that should be made is that the lower virulence of human flu is the mechanism by which this virus has remained endemic in humans and infects millions year in year out. If it were highly virulent, like H5N1, it would kill too many hosts to be persistent year in year out. As a dead host cannot infect another in the same way as a living one in direct contact. It is not necessarily true that H5N1 will mutate immediately into such a persistent viral sub-strain. The likelihood is that it will mutate into a fast-infecting form initially, but such a form will remove hosts from the ecosystem too quickly to remain endemic in the way that common human flu is. Viz, we don’t see the 1918 flu today because it died out.

Crystallising thoughts on bird flu

UK researchers have determined the X-ray structure of a key protein of the avian influenza virus that reveals a peculiarity that might prove the Achilles’ heel of bird flu and allow new potent drugs against the disease that could stave off a flu pandemic.

H5N1 virus is named for the particular haemagglutinin (H) and neuraminidase (N) proteins that are found on the viral coat. Haemagglutinin allows the viral particles to bind to and infect host cells, while neuraminidase helps the virus to escape infected cells and attack new ones. There are 16 H’s and 9 N’s in known variants on the influenza type A virus.

It is the neuraminidases that are the target for drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza). The trouble is, N1 is not the exact target for which they were designed. Rather the design of these drugs was based on neuraminidases N2 and N9 found in other influenza type A strains. H5N1 itself resides in a genetically distinct group. Structural information from this group could be critical to producing drugs that are resistant to emerging resistance in influenza.

Read the full story in my latest news round up at spectroscopynow.com

Bird flu reaches the US

…but it’s not the deadly strain of avian influenza (high-pathogenicity avian influenza, HPAI H5N1) that has featured in endless media speculation over the last couple of years. At a time, when the Thai authorities have announced several new cases of bird flu in their country, scientists in the US have detected the low-pathogenicity (LPAI) bird flu in wild swans near the banks of Lake Erie.

Ron DeHaven, administrator of USDA’s Animal and Plant Health Inspection Service, told the Associated Press that “We do not believe this virus represents a risk to human health.” Preliminary testing showed the presence of the H5 and the N1 sub-types in the infected Michigan birds, but the USDA explains that these are more probably present because of LPAI, which is also known as American H5N1, as opposed to Asian H5N1.

Evidence of this putative low pathogenicity avian influenza (LPAI) has been found on two occasions in wild birds in the United States. In 1975 and 1986, it was detected in wild ducks. These detections occurred as part of routine sampling. LPAI H5N1 has also been detected in Canada, most recently in 2005.

Asian H5N1 has killed at least 140 people but is yet to mutate into a form that is readily transmissable between humans. Indeed, it seems the only likely way you catch this strain is through very close proximity to infected birds (i.e. sharing living quarters) or by coming into contact with feces from an infected bird.

More on the Michigan bird flu story…

Bird flu drugs

In the latest issue of The Alchemist on ChemWeb.com I provide a round-up of the week’s chemistry news, of particular importance could be news that UK and Australian researchers may have found a new way to approach drug design for bird flu viruses that precludes drug resistance.

A new drug to fight bird flu that should be able to side-step the emergence of viral resistance is being developed by Andrew Watts of the University of Bath, UK and Jennifer McKimm-Breschkin of CSIRO Australia. Both Tamiflu and Relenza, the two drugs currently being stockpiled by governments in preparation for a global outbreak of bird flu, are inherently susceptible to resistance because of the way they work. Although the new drug acts on the same target as these treatments, the enzyme neuraminidase, it targets a specific region of the enzyme that essential to its function. If this region mutates the virus would no longer be viable, so that resistance cannot emerge.

Read about this and more in this week’s Alchemist.

Needle free bird flu vaccine

A needle-free, DNA-based, vaccine against avian influenza strain H5N1 has been developed by UK company Powder Med Ltd and will soon enter clinical trials.

This new vaccine is based upon PowderMed’s proprietary system for delivering DNA
vaccines — it is a needle-free injection device that fires gold particles coated with DNA
(encoding genes specific to the flu strain) at supersonic speed into the immune cells of
the skin. This first-time-in-man clinical trial will examine the ability of a vaccine based
upon the Vietnam H5N1 avian influenza strain to protect against a potential pandemic
form of flu.

A previous study, conducted by PowderMed in the United States, demonstrated that this
vaccine technology was able to produce 100% protective immune responses in adult
volunteers to a vaccine which encoded an annual influenza strain

Of course, who’s to say H5N1 will be the cause of the imminent bird flu epidemic or indeed that any avian influenza strain will be the next big viral attack on the human race. There are also sorts of terrifying possibilities lying dormant in exotic hosts the world over…think SARS…think HIV…think ebola…

This is my report from the Royal Society on emerging viral infections

Britain unprepared for flu pandemic shock

Reuters is reporting that general practitioner Steve Hajioff warns that the UK’s preparations for a bird flu pandemic are inadequate.

The UK is on high alert for bird flu following the dead swan incident in Scotland and is stockpiling vaccine. Hajioff, however, suggests that the impact on infrastructure of an avian influenza epidemic would be like a thousand 9/11’s. “In the present day, you are talking about five million people across Europe and hundreds of thousands in the UK. It’s like 1,000 September 11ths all at once,” he said.

The insensitivity of such a phrase aside, Hajioff went on to tell BBC radio: “I’m a GP and I can prepare my surgery, but if the electricity company that supplies my power has not prepared, then I am not going to be able to treat patients.”

What worries me, is whether or not Dr Hajioff is qualified to offer a new thread to the scare-mongering surrounding bird flu in this way. Maybe he is. His website tells us he “is a broadcaster, a healthcare informatics consultant, a public health physician, and a writer.” It goes on to say that he has a particular interest in international health systems, communicable disease control and electronic data security.” Interestingly(?), “For fun, he paints, skis, cooks and drives his MG. He is also a keen MIDI musician.”

And, seeing as the reporting on his offering to BBC Radio suggests he didn’t actually tell the audience anything that isn’t fairly obvious then perhaps he is qualified after all.

Just for the record, despite the continued scaremongering for almost every H5N1 is yet to mutate into a human transmissable form and the evidence points to the likelihood that such a mutant would have less virulence among humans than H5N1 has among birds.

We’ll see.

H5N1 Vaccine Available

cockerelElena Govorkova and colleagues at St. Jude Children’s Research Hospital in Memphis, Tennessee, have developed a vaccine against the potential lethal H5N1 strain of avian influenza. The vaccine protects, it seems, without triggering antibody production as is normally the case.

While lab tests show the vaccine to be effective, there is a problem with this preliminary study. It was not carried out on humans, so we shall not know whether it would be of any use should a pandemic arise. But, at least the laboratory ferrets, will be protected.